Tirofiban-hydrochloride-monohydrate-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETirofiban hydrochloride monohydrateCat. No.: HY-17369CAS No.: 150915-40-5分式: CHClNOS分量: 495.07作靶點(diǎn): Integrin作通路: Cytoskeleton儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 12 mg/mL (24.24 m

2、M; Need ultrasonic and warming)H2O : 0.1 mg/mL (insoluble)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.0199 mL 10.0996 mL 20.1992 mL5 mM 0.4040 mL 2.0199 mL 4.0398 mL10 mM 0.2020 mL 1.0100 mL 2.0199 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Tirofiban鹽酸鹽合物肽類，糖蛋IIb/I

3、IIa拮抗劑。REFERENCES1. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets.2008 Jun;8(2):138-46.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE2. van t Hof AW, Valgimigli M. Defining the role of platelet glycoprotein recep

4、tor inhibitors in STEMI: focus on tirofiban. Drugs.2009;69(1):85-100.3. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronaryintervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.4. Valgi

5、migli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.5. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients withST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul1;9(3):147-53.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;